Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of SHR-1905 in healthy subjects
NCT04800263Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Jul 2021
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SHR-1905 in asthma (5 arms), sponsored by Atridia Pty Ltd. Primary endpoint: Adverse events at 16 weeks. Started Jul 2021; status: completed.
02
Drugs
SHR-1905
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04800263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04800263.